ADVANCING A DIVERSE PIPELINE WITH INCREDIBLE PROMISE

Our innovative pipeline focuses on the development of a diverse array of next-generation therapies including Probody cancer immunotherapies, Probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and Probody-enabled chimeric antigen receptor natural killer (ProCAR-NK) cell therapies.

Each of these therapeutic modalities has shown incredible potential, with unique advantages in terms of treatment scenarios, bringing forth new options for powerful drugs that have previously been limited by toxicity concerns.

Roll over each program to expand text.